Literature DB >> 3068641

The low-dose model of UVB-induced immunosuppression.

P D Cruz1, P R Bergstresser.   

Abstract

Recent interest in photoimmunology has led to the development of the low-dose model of UVB-induced immunosuppression, an experimental framework in which inhibition of contact hypersensitivity is associated with alterations in the morphology and the antigen-presenting function of Langerhans cells in locally irradiated skin, and with the appearance of hapten-specific T-suppressor cells in systemic circulation. This article reviews the scientific data that has been generated from the utilization of this model. It focuses particular attention on current evidence that identifies distinct epidermal cell populations as key sources of the immunosuppression evoked by low-dose UVB.

Entities:  

Mesh:

Year:  1988        PMID: 3068641

Source DB:  PubMed          Journal:  Photodermatol        ISSN: 0108-9684


  4 in total

1.  DC-HIL is a negative regulator of T lymphocyte activation.

Authors:  Jin-Sung Chung; Kota Sato; Irene I Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

2.  Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease.

Authors:  Hideo Akiyoshi; Jin-Sung Chung; Mizuki Tomihari; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2010-02-22       Impact factor: 5.422

3.  Effects of acute, low-dose UVB radiation on the induction of contact hypersensitivity to diphenylcyclopropenone in man.

Authors:  A Friedli; T Hunziker; B Finkel; L R Braathen
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

4.  Localization of DNA damage and its role in altered antigen-presenting cell function in ultraviolet-irradiated mice.

Authors:  A A Vink; F M Strickland; C Bucana; P A Cox; L Roza; D B Yarosh; M L Kripke
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.